FDA Biosimilar Interchangability Regulations Completed

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

lord999

Full Member
Moderator Emeritus
Lifetime Donor
20+ Year Member
Joined
Feb 21, 2002
Messages
4,444
Reaction score
4,841
Points
6,826
Location
DC
  1. Pharmacist
  2. Academic Administration


That's going to be very interesting for BIO. I wouldn't suggest dumping your Amgen or Genentech yet, but the biologics market is going to be interesting in about five to seven years from now.
 
Developing biosimilars for biologics seems like a daunting task since most all of them are monoclonal antibodies.
 
Top Bottom